{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:06:48Z","timestamp":1790165208460,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rpth.2026.106847","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:39:56Z","timestamp":1785800396000},"page":"106847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Etiology and management of venous thromboembolism recurrence in patients anticoagulated for venous thromboembolism: a single-center study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-6768","authenticated-orcid":false,"given":"Nichole","family":"Brunton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar E.","family":"Wysokinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle T.","family":"Vlazny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"McBane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon E.","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Casanegra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106847_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMcp2116489","article-title":"Pulmonary embolism","volume":"387","author":"Kahn","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106847_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1160\/TH17-08-0531","article-title":"Acute pulmonary embolism in a National Danish Cohort: increasing incidence and decreasing mortality","volume":"118","author":"Lehnert","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106847_bib3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106847_bib4","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106847_bib5","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"EINSTEIN\u2013PE Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106847_bib6","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106847_bib7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106847_bib8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jth.14752","article-title":"Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D trial (SELECT-D: 12m)","volume":"18","author":"Marshall","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106847_bib9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106847_bib10","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC subcommittee on control of anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106847_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.thromres.2019.04.021","article-title":"Patient-level adherence and interventions in an interdisciplinary DOAC clinic","volume":"179","author":"Talana","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106847_bib12","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jth.15823","article-title":"Direct oral anticoagulants after bariatric surgery\u2014what is the evidence?","volume":"20","author":"Leong","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106847_bib13","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jacc.2019.12.068","article-title":"Select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week","volume":"75","author":"Wiggins","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2026.106847_bib14","author":"Barnes"},{"key":"10.1016\/j.rpth.2026.106847_bib15","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.mayocp.2018.09.022","article-title":"Apixaban and rivaroxaban in patients with acute venous thromboembolism","volume":"94","author":"Bott-Kitslaar","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.rpth.2026.106847_bib22","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s12325-022-02391-z","article-title":"Venous thromboembolism recurrence among patients who abandon oral anticoagulant therapy in the USA: a retrospective longitudinal study","volume":"40","author":"Alberts","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.rpth.2026.106847_bib23","first-page":"377","article-title":"Recurrent venous thromboembolism","volume":"105","author":"Mount","year":"2022","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.rpth.2026.106847_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.thromres.2019.06.017","article-title":"Management of suspected and confirmed recurrent venous thrombosis while on anticoagulant therapy. What next?","volume":"180","author":"Rodger","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106847_bib24","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1055\/a-2161-0928","article-title":"Prevalence and predictors of nonadherence to direct oral anticoagulant treatment in patients with atrial fibrillation","volume":"7","author":"van der Horst","year":"2023","journal-title":"TH Open"},{"key":"10.1016\/j.rpth.2026.106847_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2022.100175","article-title":"Reasons for nonadherence to the direct oral anticoagulant apixaban: a cross-sectional survey of atrial fibrillation patients","volume":"2","author":"Tarn","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.rpth.2026.106847_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021601","article-title":"Long-term medication adherence trajectories to direct oral anticoagulants and clinical outcomes in patients with atrial fibrillation","volume":"10","author":"An","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.rpth.2026.106847_bib27","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005969","article-title":"Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation","volume":"13","author":"Ozaki","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.rpth.2026.106847_bib28","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.rpth.2026.106847_bib29","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2026.106847_bib30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.amjmed.2016.12.033","article-title":"Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance","volume":"130","author":"Martin","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2026.106847_bib31","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2019-127596","article-title":"Thrombocytopenia and anticoagulation: impact of the ISTH SCC anticoagulation guidelines in patients with thrombocytopenia","volume":"134","author":"Held","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106847_bib32","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/jth.15666","article-title":"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients \u2013 30 months follow-up","volume":"20","author":"Larsen","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106847_bib33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1055\/s-0040-1718405","article-title":"Dosage of anticoagulants in obesity: recommendations based on a systematic review","volume":"46","author":"Abildgaard","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106847_bib34","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood.2022018797","article-title":"Monoclonal gammopathy of thrombotic\/thrombocytopenic significance","volume":"141","author":"Kanack","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106847_bib35","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIRCULATIONAHA.113.007665","article-title":"Cardiology patient page. Thrombophilia and hypercoagulability","volume":"130","author":"Piazza","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2026.106847_bib36","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1177\/17085381211042231","article-title":"Direct oral anticoagulants decrease treatment failure for acute lower extremity deep venous thrombosis","volume":"30","author":"Hekman","year":"2022","journal-title":"Vascular"},{"key":"10.1016\/j.rpth.2026.106847_bib37","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106847_bib38","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2026.106847_bib39","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106847_bib40","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1055\/s-0041-1735194","article-title":"Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer","volume":"122","author":"Agnelli","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106847_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.rpth.2026.106847_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.thromres.2022.11.005","article-title":"Influence of primary cancer site on clinical outcomes of anticoagulation for associated venous thromboembolism","volume":"221","author":"Wysokinski","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106847_bib46","first-page":"231","article-title":"May-Thurner syndrome: a not so uncommon cause of a common condition","volume":"25","author":"Peters","year":"2012","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.rpth.2026.106847_bib47","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/jth.14707","article-title":"May-Thurner syndrome: history of understanding and need for defining population prevalence","volume":"18","author":"Harbin","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106847_bib48","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rpth.2026.106847_bib49","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106847_bib50","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1182\/blood-2018-99-111108","article-title":"Treatment failure in patients receiving direct oral anticoagulants: clinical management and outcomes from a single-center review of 59 consecutive patients","volume":"132","author":"McIlroy","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106847_bib51","article-title":"Minimizing recurrent venous thromboembolism","volume":"366","author":"Bikdeli","year":"2019","journal-title":"BMJ"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:50:15Z","timestamp":1790164215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2475037926035053"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106847","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etiology and management of venous thromboembolism recurrence in patients anticoagulated for venous thromboembolism: a single-center study","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106847","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106847"}}